However, SQ20B tumors exhibited intermediate sensitivity to anti-EGFR therapy, with accelerated regrowth at the end of treatment (positively stained carcinoma cells remained after treatment; Figure 1B,C; Figure S2A). The gene discussed is EGFR; the disease is carcinoma.